Neuroinflammation as an Integral Component of Neurodegeneration in Parkinson's Disease
Authors:
- 18 December 2024
- journal article
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in Personalized Psychiatry and Neurology
- Vol. 4 (4)
Abstract
Parkinson's disease (PD) is a progressively advancing neurodegenerative disorder, the pathogenetic mechanisms of which remain poorly understood. The disease is characterized by the degeneration of dopaminergic neurons in the substantia nigra of the midbrain. Given the improvement in the quality of medical care provided to the population, it is projected that the total number of patients diagnosed with PD worldwide will rise to 8.7 million by 2030. This review addresses the fundamental aspects of neuroinflammation in the context of PD pathogenesis. There is no doubt that pro-inflammatory immunological mechanisms play a critical role in the onset and progression of the disease. Neuronal-derived cells, such as microglia and astrocytes, act as inducers of neuroinflammation, affecting the permeability of the blood-brain barrier to peripheral immune-competent cells. Furthermore, cytokine patterns of the immune response in PD appear to exist. Potential therapeutic approaches for mitigating neuroinflammation in PD, which have been studied in experimental and in vitro models, are also discussed.Keywords
This publication has 61 references indexed in Scilit:
- Microglia in Parkinson’s Disease2019
- Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysisEuropean Journal of Clinical Pharmacology, 2018
- Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel DiseaseJAMA Neurology, 2018
- Th9 cells in the pathogenesis of EAE and multiple sclerosisSeminars in Immunopathology, 2016
- The role of inflammation in sporadic and familial Parkinson’s diseaseCellular and Molecular Life Sciences, 2013
- Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesCochrane Database of Systematic Reviews, 2011
- Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation updateHuman Mutation, 2010
- Role of cytokines in inflammatory process in Parkinson’s disease2006
- Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brainsActa Neuropathologica, 2004
- Microglia as a source and target of cytokinesGlia, 2002